This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, C. D. Articles by Moore, R. E. Search for Related Content PubMed PubMed Citation Articles by Smith, C. D. Articles by Moore, R. E.

Cryptophycin: A New Antimicrotubule Agent Active against Drug-resistant Cells¹

Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii 96813

Cryptophycin is a cytotoxic dioxadiazacyclohexadecenetetrone isolated from cyanobacteria of the genus Nostoc. Incubation of L1210 leukemia cells with cryptophycin resulted in dose-dependent inhibition of cell proliferation in parallel with increases in the percentage of cells in mitosis (half-maximal effects at <10 pM). Indirect immunofluorescence studies demonstrated that treatment of A-10 vascular smooth muscle cells with cryptophycin results in marked depletion of cellular microtubules and reorganization of vimentin intermediate filaments, similar to the effects of vinblastine. Cytochalasin B caused the depolymerization of microfilaments in these cells, while neither vinblastine nor cryptophycin affected this cytoskeletal component. Pretreatment of cells with taxol prevented microtubule depolymerization in response to either vinblastine or cryptophycin. While microtubule depolymerization in response to vinblastine was rapidly reversed by removal of the drug, cells treated with cryptophycin remained microtubule depleted for at least 24 h after removal of the compound. Combinational treatments with vinblastine and cryptophycin resulted in additive cytotoxicity. Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol. Therefore, cryptophycin is a new antimicrotubule compound which appears to be a poorer substrate for P-glycoprotein than are the Vinca alkaloids. This property may confer an advantage to cryptophycin in the chemotherapy of drug-resistant tumors.

¹ This work was supported in part by the State of Hawai, Office of Technology Transfer and Economic Development (C. D. S.) and NIH Grant CA 12623 (R. E. M.).

² To whom requests for reprints should be addressed, at Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111.

Received 2/ 4/94. Accepted 5/13/94.

This article has been cited by other articles:

				H. E. Rasmussen, K. R. Blobaum, Y.-K. Park, S. J. Ehlers, F. Lu, and J.-Y. Lee Lipid Extract of Nostoc commune var. sphaeroides Kutzing, a Blue-Green Alga, Inhibits the Activation of Sterol Regulatory Element Binding Proteins in HepG2 Cells J. Nutr., March 1, 2008; 138(3): 476 - 481. [Abstract] [Full Text] [PDF]

				J. P. Stevenson, W. Sun, M. Gallagher, R. Johnson, D. Vaughn, L. Schuchter, K. Algazy, S. Hahn, N. Enas, D. Ellis, et al. Phase I Trial of the Cryptophycin Analogue LY355703 Administered as an Intravenous Infusion on a Day 1 and 8 Schedule Every 21 Days Clin. Cancer Res., August 1, 2002; 8(8): 2524 - 2529. [Abstract] [Full Text] [PDF]

				K.-H. Chi, H.-E. Wang, F.-D. Chen, Y. Chao, R.-S. Liu, S.-L. Chou, Y.-S. Wang, and S.-H. Yen Preclinical Evaluation of Locoregional Delivery of Radiolabeled Iododeoxyuridine and Thymidylate Synthase Inhibitor in a Hepatoma Model J. Nucl. Med., February 1, 2001; 42(2): 345 - 351. [Abstract] [Full Text]

				T. M. De Pas, M. Mandala, G. Curigliano, and F. Peccatori ACUTE VULVAR VESTIBULITIS OCCURRING DURING CHEMOTHERAPY WITH CRYPTOPHYCIN ANALOGUE LY355703 Obstet. Gynecol., June 1, 2000; 95(6): 1030 - 1030. [Full Text] [PDF]

				L. M. Leoni, E. Hamel, D. Genini, H. Shih, C. J. Carrera, H. B. Cottam, and D. A. Carson Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells J Natl Cancer Inst, February 2, 2000; 92(3): 217 - 224. [Abstract] [Full Text] [PDF]

				C. Dumontet and B. I. Sikic Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death J. Clin. Oncol., March 1, 1999; 17(3): 1061 - 1061. [Abstract] [Full Text] [PDF]

				D. Panda, K. DeLuca, D. Williams, M. A. Jordan, and L. Wilson Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends PNAS, August 4, 1998; 95(16): 9313 - 9318. [Abstract] [Full Text] [PDF]

				C. D. Smith and X. Zhang Mechanism of Action of Cryptophycin J. Biol. Chem., March 15, 1996; 271(11): 6192 - 6198. [Abstract] [Full Text] [PDF]